

# WORLD-CLASS DIAGNOSTIC INNOVATIONS FROM FINLAND

---

BUSINESS  
FINLAND

#FINLANDWORKS



# TABLE OF CONTENTS

---

BUSINESS  
FINLAND

1. Why Finland?
2. High-level business ecosystems and research
3. Variety of solutions – from predictive healthcare to high-end devices
4. Early detection enables more effective treatment
5. Improved diagnostic accuracy and patient outcomes
6. Solutions for empowering healthier life for patients
7. Your partner in designing and manufacturing medical devices
8. Business Finland

# WHY FINLAND?

---

**BUSINESS  
FINLAND**

FINLAND IS A SMALL GIANT IN THE FIELD OF DIAGNOSTICS DUE TO ITS STRONG COLLABORATION AMONG HIGH-LEVEL ACADEMIC RESEARCH, STRONG ENGINEERING SKILLS AND IRREPRESSIBLE ENTREPRENEURIAL SPIRIT.

## #1

### **WORLD LEADER IN DIAGNOSTICS**

Finland has a long-term national commitment to be an international hub for versatile and high-quality scientific research and a springboard for innovations. The Finnish ecosystem offers excellent possibilities for conducting clinical research into modern technologies and treatments, as well as providing access to an advanced network of test beds.

## #2

### **GOVERNMENT BACKING**

Finland has one of the most efficient healthcare systems – offering high value for money spent. Business-friendly legislation enables access to health data and biological specimens for research and development.

## #3

### **HOME FOR WORLD- CLASS INNOVATIONS**

The diagnostics industry is one of Finland's strengths in health technology. We are home to global R&D centers of excellence for many leading companies, including PerkinElmer, GE Healthcare and Thermo Fisher Scientific. Finland is a global partner in public-private collaboration and supported by innovation-friendly legislation.



# WHY FINLAND?

---

BUSINESS  
FINLAND

**THE BEST  
UNIVERSITY-  
INDUSTRY-RESEARCH  
COLLABORATION  
IN THE WORLD**

Global Innovation Index 2016

**THE BEST  
AVAILABILITY  
OF SCIENTISTS  
AND ENGINEERS**

World Economic Forum Global  
Competitiveness Report 2017–2018

**THE BEST  
AVAILABILITY  
OF THE LATEST  
TECHNOLOGIES**

World Economic Forum Global  
Competitiveness Report 2017–2018

**THE BEST  
IN THE WORLD  
IN INNOVATION**

World Economic Forum Global  
Competitiveness Report 2017–2018



# HIGH-LEVEL BUSINESS ECOSYSTEMS AND RESEARCH

---

BUSINESS  
FINLAND

## UNIVERSITY OF OULU

Centre for Health and Technology (CHT) at the Faculty of Medicine, University of Oulu, develops multidisciplinary, multi-stakeholder RDI network cooperation between research institutes, companies, and health service providers. As part of the OuluHealth ecosystem, CHT is building Digital Health Knowledge Partnerships and collaboration models in data-intensive research and innovation with its 10 years of experience in the field of health and wellbeing.

[Read more](#)

## UNIVERSITY OF HELSINKI

The high-quality medical research conducted at the Faculty of Medicine ranges from biological basic research to clinical applications. For instance, the Academic Medical Center Helsinki (AMCH) is an internationally renowned medical campus, comprising the Faculty of Medicine of the University of Helsinki, the HUS Helsinki University Hospital and the Institute of Molecular Medicine Finland (FIMM), which is part of the Helsinki Institute of Life Science (HiLIFE).

[Read more](#)

# HIGH-LEVEL BUSINESS ECOSYSTEMS AND RESEARCH

---

BUSINESS  
FINLAND

## UNIVERSITY OF TURKU

Turku Bioscience is an advanced core facility and research center hosted jointly by the University of Turku and Åbo Akademi University. Focus areas include cancer cell signaling, cancer proteomics, cell adhesion and cancer, computational biomedicine, and cytoskeletal and survival signaling. Turku PET Centre is a Finnish national research institute for the use of short-lived positron-emitting isotopes in the field of medical research. All facilities are located at the university campus and clinics. The center consists of an accelerator Laboratory, radiopharmaceutical chemistry laboratory and preclinical and clinical imaging laboratories.

[Read more](#)

## TAMPERE UNIVERSITY

Tampere University Faculty of Medicine and Health Technology (MET) has a unique combination of biomedical engineering, cell and molecular biology and clinical medicine providing a seedbed for new therapeutic and diagnostic innovations, and business opportunities. The faculty is dedicated to pursue world-class research with expertise on such diagnostics technologies as bioimaging, biosensors, microfluidics, physiological measurements, health data science and computational biology, advanced in protein technology, genetic analysis, in vitro cell and tissue models, tissue engineering and clinical medicine.

[Read more](#)



# HIGH-LEVEL BUSINESS ECOSYSTEMS AND RESEARCH

---

BUSINESS  
FINLAND

## FUDIS

The future of Diagnostics (FUDIS) project enables the rapid introduction of diagnostic solutions to the market of fast and precise diagnostic methods for a number of diseases and healthcare challenges. These products include sensitive and multifunctional in vitro diagnostic platforms, new (bio) materials, methods for manufacturing diagnostic tests, equipment for reading results and biomarkers.

[Read more](#)

## FINBB

FINBB connects researchers to Finnish biomedical research via Fingenious®, services, available via a digital service built to serve academic and industry researchers globally. Using Fingenious®, researchers can connect with a single click to all Finnish public biobanks, including six regional hospital biobanks and the national THL Biobank.

[Read more](#)

## VTT

VTT Technical Research Centre of Finland is actively involved in the Finnish Smart Health ecosystem, supporting the utilization of the health data compiled in national registers for the development of new treatment methods, drugs and wellness products.

[Read more](#)

# VARIETY OF SOLUTIONS – FROM PREDICTIVE HEALTH CARE TO HIGH-END DEVICES

---

BUSINESS  
FINLAND

## 1. IN VITRO DIAGNOSTICS (IVD): EARLY DETECTION ENABLES MORE EFFECTIVE TREATMENT

Abacus Diagnostica Oy  
Abomics Oy  
Actim Oy  
Aidian Oy  
ArcDia International Ltd  
Biohit Oy  
Hologic, Inc.  
HyTest Oy  
Kaivogen Oy  
Labquality Oy  
LS CancerDiag Ltd  
Oy Reagen Ltd  
Tammer BioLab Oy  
Te?ted Oy  
Thermo Fisher Scientific Oy  
Wallac Oy

## 2. MEDICAL IMAGING: IMPROVED DIAGNOSTIC ACCURACY AND PATIENT OUTCOMES

Aiforia Technologies Oy  
Bone Index Finland Oy  
Combinostics Oy  
Disior Oy  
Euformatics Oy  
Grundium Oy  
Icare Finland Oy  
Optomed Oy  
Planmed Oy

## 3. PATIENT AND HOME MONITORING: SOLUTIONS FOR EMPOWERING A HEALTHIER LIFE FOR PATIENTS

BrainCare Oy  
Cerenion Oy  
Heart2Save Oy  
Nukute Oy  
VitalSignum Oy

## 4. CONTRACT MANUFACTURING: YOUR PARTNER IN DESIGNING AND MANUFACTURING MEDICAL DEVICES


ESiOR Oy  
Innokas Medical Ltd.  
Labrox Oy  
Mylab Oy  
Screentec Oy  
Tepcomp Group Oy



# 1. IN VITRO DIAGNOSTICS (IVD)

---

EARLY DETECTION ENABLES MORE EFFECTIVE  
TREATMENT



# RAPID AND SIMPLE MOLECULAR DIAGNOSTICS

## OUR SOLUTION

GenomEra® CDX provides a powerful tool to run rapid PCR tests routinely and cost efficiently without compromising the quality of results. Currently, our product portfolio consists of 9 CE IVD rapid PCR and RT-qPCR tests for the detection of infectious diseases, such as COVID-19, influenza, C. difficile and norovirus.

## BENEFITS & REFERENCES

With its automated assay protocol requiring minimal hands-on time, GenomEra® CDX significantly reduces the workload of laboratory personnel.

The rapid system provides results from four individual samples in only 50–70 minutes while maintaining excellent sensitivity and specificity.

Due to the simplicity of the system, no prior experience in PCR nor dedicated PCR facilities are required.

With a constantly expanding distribution network, Abacus already has customers in 20+ countries.

## COMPANY

Abacus Diagnostica is a rapidly growing molecular diagnostic company. Since its inception in 2004, Abacus has been working hard to provide reliable diagnostic tools suitable for use in settings with limited resources and capabilities. With customer needs as a priority, we take pride in our efficient and high-quality customer service.

## CONTACT

**Erno Sundberg**  
CEO

[erno.sundberg@abacusdiagnostica.com](mailto:erno.sundberg@abacusdiagnostica.com)

+358 40 727 8690

[www.abacusdiagnostica.com](http://www.abacusdiagnostica.com)





# PHARMACOGENETICS FOR DAILY CLINICAL DECISION-MAKING

## OUR SOLUTION

Pharmacogenetics is the science that combines genetics with pharmacology. Your genes dictate how you react to a certain medicine. This is individual for all of us, and this science can be used to personalize medication for individual patients. Pharmacogenetics is disrupting medication, as the cost of genetic testing has dropped from thousands of euros to hundreds of euros.

At Abomics, we make pharmacogenetics a simple tool for doctors in their daily clinical work. Based on a simple blood test, we provide doctors with a patient-specific report that shows whether a particular medicine is suitable for a patient or not and how the dosage should be adjusted.

## BENEFITS & REFERENCES

Scientific evidence shows that pharmacogenetics gives better clinical outcomes for the patient and better cost efficiency for society. This is particularly true in the treatment of depression and geriatric polypharmacy.

Evidence is strong also in the treatment of coronary heart disease, thrombosis and stroke. Precision medicine is available for your patients today.

## COMPANY

Abomics was founded in 2013 by two medical doctors, Jari Forsström and Klaus Elenius. We offer pharmacogenetic solutions for both clinical laboratories and healthcare providers.

## CONTACT

**Valter Rönholm**  
CEO

[valter.ronnholm@abomics.fi](mailto:valter.ronnholm@abomics.fi)  
+358 40 523 9110  
[www.abomics.fi](http://www.abomics.fi)

Actim®  
SARS-CoV-2

+

Actim®  
Influenza A&B

Common cold,  
influenza or  
COVID-19?

Actim

## QUICK DIAGNOSIS – RIGHT TREATMENT

### OUR SOLUTION

Actim® tests are high-quality diagnostic rapid tests for healthcare professionals all around the world. For nearly 30 years, Actim tests have been used to support reliable diagnosis of various diseases. Our product range offers top-class tests for pregnancy monitoring, gastrointestinal and infectious diseases testing, including our newest: Actim SARS-CoV-2 + Actim Influenza A&B tests.

### BENEFITS & REFERENCES

Actim® rapid tests stand for accuracy, practicality and fast diagnosis. Our products can be used at the point of care, without the need for laboratory equipment. The easy sampling method and one-step test procedure provide convenience for both the patient and the medical staff. Actim tests help in choosing the right treatment, right when it's needed.

### COMPANY

We are Actim – one of the subsidiaries of the Finnish biotechnology group Medix Biochemica. Our company specializes in developing and producing innovative rapid diagnostic tests for healthcare professionals.

### CONTACT

**Laura Kanto**  
Product Line Manager

[laura.kanto@actimtest.com](mailto:laura.kanto@actimtest.com)  
+358 9 547 680  
[www.actimtest.com](http://www.actimtest.com)





# QUIKREAD GO® FOR POINT OF CARE

## OUR SOLUTION

Aidian's flagship product – the QuikRead go® point-of-care system – supports instant diagnosis and treatment management at various types of healthcare sites.

Our user-friendly QuikRead go is a fully automatic and portable system providing laboratory-quality results in minutes for analytes, such as CRP, CRP+Hb, Strep A, HbA1c and FIT (iFOB).

## BENEFITS & REFERENCES

Aidian has a proven track record in developing and manufacturing point-of-care solutions.

We are seeking licensees and partnering opportunities for SIBA®, our exclusive, IPR-protected, isothermal amplification technology. Aidian's proprietary strand invasion-based isothermal technology SIBA is suitable for POC solutions where robustness and time-to-results are crucial.

## COMPANY

Aidian, previously Orion Diagnostica, is a Finnish-based IVD company with almost 50 years of experience developing and manufacturing reliable, fast and easy-to-use diagnostic tests especially for point of care.

In addition to our own products, we market products from well-known suppliers. Aidian has sales units in 11 countries in Northern and Central Europe and distributors in over 60 countries.

## CONTACT

**Gabriella von Flittner**  
Chief Marketing Officer

[gabriella.flittner@aidian.eu](mailto:gabriella.flittner@aidian.eu)

+358 50 381 0550

[www.aidian.eu](http://www.aidian.eu)



# AUTOMATED RAPID TESTING OF INFECTIONS SUCH AS COVID-19

## OUR SOLUTION

Our fully automated mariPOC® test system brings central laboratory quality and performance to the sampling site. Multiple pathogens can be quickly tested from only a swab sample. mariPOC provides reliable results with a very handy, quick procedure. It is perfectly suited for adult and pediatric emergency wards and for workplace testing during epidemics.

## BENEFITS & REFERENCES

mariPOC ensures optimal diagnosis, treatment and management of acute infections, such as influenza, pharyngitis and gastroenteritis. It enables optimal use of antibiotics and antiviral drugs and predicts the clinical course.

mariPOC can be installed and operated at the sampling site by healthcare personnel without laboratory training. The results can be sent to patient data management systems. mariPOC is available in 30 countries worldwide.

## COMPANY

ISO 13485-certified ArcDia International Ltd, based in Turku, Finland, develops, manufactures and markets automated random-access diagnostics for rapid multianalyte identification of pathogens, antimicrobial resistance and surveillance.

The platform is based on proprietary mariPOC technology for decentralized diagnostics. It addresses healthcare's largest problems and enables a fast development of solutions for emerging pandemics. The platform is available for clinical diagnostic use, R&D, licensing and distribution.

## CONTACT

**Vesa Kemppainen**  
CEO

[vesa.kemppainen@arcdia.com](mailto:vesa.kemppainen@arcdia.com)  
+358 40 678 7414  
[www.arcdia.com](http://www.arcdia.com)





# A UNIQUE METHODS TO DETECT STOMACH CANCER RISKS

## OUR SOLUTION

Revolutionary quick test innovation of the unique GastroPanel® is now available! GastroPanel® quick test is the further development of the unique Biohit GastroPanel examination. GastroPanel quick test allows fast diagnosis of and screening for Helicobacter pylori, atrophic gastritis with related risks as well as high acid output of stomach in symptomatic and asymptomatic patients. The GastroPanel quick test speeds up the referral to further examinations.

GastroPanel® findings – including Helicobacter pylori infection, atrophic gastritis or high acid output – are indications for gastroscopy and biopsy examination. GastroPanel® quick test saves costs and unnecessary clinical appointments. It significantly improves patient safety, as it speeds up the referral to further examinations, treatment and follow-up.

## BENEFITS & REFERENCES

GastroPanel® is a first-line diagnostic test for dyspeptic patients. It is a non-invasive, risk-free and user-friendly laboratory blood test. GastroPanel detects Helicobacter pylori infections and atrophic gastritis (mucosal atrophy) caused by helicobacter

or autoimmune disease, discloses the associated risks like gastric and esophageal cancer as well as malabsorption of B12 vitamin, calcium, magnesium, zinc, iron and certain medicines.

## COMPANY

Biohit Oyj is a Finnish biotechnology company operating in global markets. Our mission, “Innovating for Health,” describes our innovative products and services. Working with the scientific community, Biohit produces new technologies, products and services based on research results and innovations that are used to develop safe and cost-effective diagnostic tests for the early detection and prevention of gastrointestinal tract diseases.

## CONTACT

**Ilari Patrakka**  
Sales and Marketing Director

[ilari.patrakka@biohit.fi](mailto:ilari.patrakka@biohit.fi)  
+358 50 381 8818  
[www.biohithealthcare.com](http://www.biohithealthcare.com)



# DELIVERING THE ACCURACY TO IMPROVE EARLY DETECTION AND TREATMENT

## OUR SOLUTION

One size does not fit all when it comes to diagnostics. From a single patient rapid result in about an hour to population level screening, Hologic can meet the diagnostic needs of laboratories today and in the future with its Molecular Scalable Solutions portfolio (including the Panther® and Novodiag® Systems).

## BENEFITS & REFERENCES

Hologic's portfolio of systems has expanded with the addition of the on-demand, molecular-testing Novodiag® System from Mobidiag. Novodiag System offers simple and fast way to diagnose patients most at risk with on-demand laboratory testing. This innovative technology is precision engineered for simplicity, accuracy and affordability.

For laboratories requiring systems with a higher throughput, Hologic's Panther Scalable Solutions offer a range of options with a broad menu of high performing assays (e.g. sexually transmitted diseases, respiratory infections).

## COMPANY

Hologic, Inc. is an international innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

In June 2021, Hologic Inc. acquired Mobidiag Ltd., a Finnish company offering molecular diagnostic solutions for Gastrointestinal Infections, Antimicrobial Resistance Management, Healthcare Associated Infections and Respiratory Infections.

## CONTACT

**Tuomas Tenkanen**  
Mobidiag CEO

[tuomas.tenkanen@hologic.com](mailto:tuomas.tenkanen@hologic.com)  
+358 10 5050 770  
[www.hologic.com](http://www.hologic.com)





# ANTIBODIES AND ANTIGENS FOR IMPROVED PATIENT OUTCOMES

## OUR SOLUTION

Since 1994, HyTest has developed and supplied immunological reagents for the IVD industry and research community. Nowadays, we provide products for several clinical and research areas. We are proud to be a leading provider of reagents for troponin I immunoassays and for certain infectious diseases like SARS-CoV-2 antigen tests.

## BENEFITS & REFERENCES

We are renowned for uncompromised quality that extends from product development to safe and secure deliveries worldwide. Continuous investment in scientific research forms a solid foundation for our product development. Our ISO 9001-certified operations ensure that our products meet the highest levels of quality.

We have established a subsidiary in Shanghai and have expanded our team to North America to improve our customer service and operations worldwide.

## COMPANY

At HyTest, we manufacture monoclonal antibodies and antigens that are mainly used as the key components of laboratory tests. Our company is one of the most important raw material suppliers for the IVD industry.

## CONTACT

**Juhana Rauramo**  
CEO

[juhana.rauramo@hytest.fi](mailto:juhana.rauramo@hytest.fi)  
+358 2 512 0943  
[www.hytest.fi](http://www.hytest.fi)



# ASSAY DEVELOPMENT AS A SERVICE

## OUR SOLUTION

Our solution includes ISO 13485-compliant ELISA kit development and production. We have an experienced team dedicated to immunoassays with a proven track record and a production capacity of up to 2,000 kit batches.

We offer off-the-shelf products like coated microplates, buffers and other reagents together with custom production for coated microplates and labeled antibodies. Our new label technology, Upcon®, developed together with Labrox, is ideal for quantitative lateral flow assays with superior sensitivity.

## BENEFITS & REFERENCES

Our wide collaborator network is used for antibody and protein production and instrument development, among other purposes. Together with the Norwegian IVD company CardiNor, we have developed an ELISA that detects secretoneurin, a marker for cardiovascular diseases. Contract manufacturing with our neighboring company Abacus Diagnostica helps them in their SARS-CoV-2 PCR kit production. Our latest assay development project is a serological SARS-CoV-2 ELISA kit, which has been developed with Actim, a fully owned Finnish

subsidiary of Medix Biochemica. Our Swedish customer has measured over 50 million patient results with ELISA kits including Kaivogen's streptavidin plate.

## COMPANY

Kaivogen Oy is a Finnish biotech company established in 2007. The word "kaivo" in the company name is Finnish for the well of a microplate and relates to the company's very first products – streptavidin-coated plates.

Since its start with these products, Kaivogen has extended its portfolio year after year. Kaivogen has a headcount of 26 at the moment, and our turnover has been around EUR 2 million for the past 5 years.

## CONTACT

**Veikko Wahlroos**  
Head of Marketing

[veikko.wahlroos@kaivogen.com](mailto:veikko.wahlroos@kaivogen.com)  
+358 44 584 5062  
[www.kaivogen.com](http://www.kaivogen.com)



# LABQUALITY



PATH TO PERFECT QUALITY

## FORERUNNER IN QUALITY

### OUR SOLUTION

Labquality is an independent service company focused on quality assurance for medical laboratories and point-of-care testing. Our clinically relevant external quality assessment (EQA) programs and quality controls are recognized internationally.

Labquality also offers regulatory expertise and services to medical device and IVD device manufacturers. We promote quality and patient safety.

### BENEFITS & REFERENCES

Labquality's External quality assessment (EQA) schemes are designed to monitor and improve the performance of medical laboratories and point-of-care testing sites. New integrated EQA programs integrate pre- and post-analytical EQA schemes with traditional analytical EQA, providing full support for ISO 15189 standard requirements.

Our Internal quality assurance (IQAS) includes all the measures to ensure that the results of laboratory instruments or point-of-care tests are correct and reproducible from one measurement to another.

Calibrators and reference materials are used to ensure the accuracy of the results. Labquality helps medical and in vitro diagnostics device (IVD) manufacturers to acquire CE markings and global regulatory approvals and plan quality management systems.

### COMPANY

Labquality is a full-service quality company that has been involved in the promotion of patient safety for over 50 years. We are the only Finnish company to offer customized quality assessment, certification and training services that are specifically designed for the health and social care sector.

### CONTACT

**Juha Wahlstedt**  
Head of Sales

[juha.wahlstedt@labquality.fi](mailto:juha.wahlstedt@labquality.fi)  
+358 9 8566 8200  
[www.labquality.com](http://www.labquality.com)



# EASY AND EARLY DETECTION OF LYNCH SYNDROME

## OUR SOLUTION

With superior accuracy, DiagMMR® detects the world's most common cause of inherited cancer, Lynch syndrome. Unlike current methods, DiagMMR® only requires a small skin biopsy for direct analysis. There is no need for tumor tissue or underlying clinical data. The test provides medical professionals and patients with quick, actionable results. Finding high-risk individuals and families early improves health outcomes, saves lives and substantially reduces healthcare costs.

## BENEFITS & REFERENCES

With its very high prevalence of approximately 1 in 125 and its dramatically high risk of cancer, Lynch syndrome should be diagnosed as early as possible to enable preventive care. The current standard of care is still reactive and has documented shortcomings in terms of accuracy and reach. DiagMMR® is the predictive stratification tool for clinicians and geneticists to be able to identify people with Lynch syndrome and prevent new and recurring cancers.

## COMPANY

LS CancerDiag has its origins at the University of Helsinki and has successfully brought its innovation to the domestic market. The test is CE marked as an in vitro diagnostics medical device (IVD MD) and is used by leading institutions like the Helsinki University Hospital.

The company is now making DiagMMR® available internationally and is looking for customers who want to be at the forefront of cancer prevention.

## CONTACT

**Philippe Arnez**  
Chief Business Officer

[philippe.arnez@lscancerdiag.com](mailto:philippe.arnez@lscancerdiag.com)


+358 40 627 8555

[www.lscancerdiag.com](http://www.lscancerdiag.com)

**LS CancerDiag**







## A VISIBLE DIFFERENCE

### OUR SOLUTION

Reagent has a strong background in developing and producing high-quality rapid tests and EIA immunoassays as well as a wide range chemical solutions. In addition, Reagent offers contract manufacturing services covering both diagnostics and liquid-based products.

### BENEFITS & REFERENCES

Reagent's core competencies include: Development of award-winning immunological point-of-care tests and enzyme immunoassays for diagnosing infectious diseases, such as Lyme, tick-borne encephalitis and hantavirus. Production of reagents, staining solutions, buffers and fixatives for life sciences and industry. Execution of contract manufacturing and product development services. Distribution of leading diagnostics brands in the Nordic region.

Reagent's products are manufactured according to the ISO 9001- and ISO 13485-certified quality management systems. The company works closely with its partners and customers to provide them with innovative products while adding value to their processes.

### COMPANY

Reagent was established in 1987. Reagent is a fast-growing biotechnology company manufacturing and selling internationally proven quality products for healthcare laboratories, industry and pharmacies.

Reagent is recognized as a reliable business partner both in global and domestic markets thanks to its combination of quality products and an agile way of working. The foundation of the company is wide knowledge and expertise in chemistry, both in clinical settings and other areas of life sciences. Reagent is headquartered in Siilinjärvi, Finland, and has distributors worldwide.

### CONTACT

**Kari Melanen**  
Vice President

[kari.melanen@reagent.com](mailto:kari.melanen@reagent.com)  
+358 40 752 6761  
[www.reagent.com](http://www.reagent.com)



# WIDE RANGE OF CUSTOMIZED MICROBIAL CULTURE MEDIA

## OUR SOLUTION

High quality, flexibility and fast service are the key words in our service. We produce nearly 200 different culture media and sample collection products and a significant number of these are CE-IVD products for clinical diagnostics. If custom made product or contract manufacturing is needed, we are an optimal partner for your business! Our products range from petri dishes, culture bottles, tailored jars, and tubes to sterile vials and injection bottles.

## BENEFITS & REFERENCES

We are experts on microbiology and production of pure or sterile culture media and sampling tubes, also in controlled clean room environment. Our production batches vary currently from 1 to 65 litres and our automation solutions enable reliable and high quality products within the wide range of products.

## COMPANY

Tammer BioLab was founded 35 years ago and is located in Tampere, Finland. We are the largest private manufacturer of microbiological culture media in the domestic market and export currently to Northern Europe. Ordering and management of documents and previous orders is easy via our versatile customer portal. Our main clienteles are clinical, veterinary, environmental, pharmaceutical, and industrial laboratories. We have been certified according to the ISO 9001 and ISO 13485 standards.

## CONTACT

**Anne Halkosalo**  
Laboratory Director

[anne.halkosalo@tammerbiolab.fi](mailto:anne.halkosalo@tammerbiolab.fi)  
+358 400 157 719  
[www.tammerbiolab.fi](http://www.tammerbiolab.fi)





# LET'S CHANGE PARADIGMS TOGETHER

## OUR SOLUTION

Teztred is innovating the way complex infectious diseases are diagnosed. Conventional tests search for only one microbe and one antibody at a time, wasting the patient's time and money. By starting multiplex testing, the clinician can develop personalized treatments and the patient recovers quicker.

## BENEFITS & REFERENCES

Joona Berghäll, award-winning Finnish film director, stated that TICKPLEX saved his life. After six years of being tested for one microbe at a time, he was tested with TICKPLEX.

With TICKPLEX, the patient needs only one visit to the doctor to be tested for 15 different microbes and 3 different disease stages. The patient then receives a highly personalized treatment protocol and can recover faster.

## COMPANY

Teztred is a medical device manufacturing company with the mission to get patients tested correctly so they can be treated properly and recover faster.

With state-of-the-art research and facilities, Teztred is able to roll out clinically validated medical devices to address global needs, such as tick-borne diseases and COVID-19.

## CONTACT

**Dr. Leona Gilbert**  
CEO

[leona.gilbert@teztred.com](mailto:leona.gilbert@teztred.com)  
+358 40 723 4718  
[www.teztred.com](http://www.teztred.com)



# MAKING THE WORLD HEALTHIER

## OUR SOLUTION

Thermo Fisher Scientific is a high-tech powerhouse known for advanced IVD systems and lab automation solutions developed and manufactured in Vantaa. With our innovative analyzers and assays, we improve clinical outcomes by enabling faster, more efficient and accurate diagnoses. By facilitating laboratory automation, we reduce manual processes and human errors.

## BENEFITS & REFERENCES

Our clinical analyzers are based on traditional photometry and on gold-standard liquid chromatography-tandem mass spectrometry (LC-MS/MS) technologies. LC-MS/MS offers enhanced accuracy, precision and specificity due to direct analyte measurement. Analyzers are fully automated for ease of use. Applications cover clinical chemistry, immunosuppressants, therapeutic drug monitoring and testing for drugs of abuse.

Our laboratory automation solution automates pre- and post-analytics, improving efficiency and increasing safety by lowering infection risks for laboratory personnel.

## COMPANY

Backed by 50+ years of experience in the IVD industry, Thermo Fisher Scientific's Vantaa Center of Excellence complies with the requirements of the FDA, ISO and other international institutions. Our products are offered through a global commercial sales force and regional distributors. We are also a trusted partner for other IVD industry companies.

## CONTACT

### **Eeva-Reetta Uitti**

Senior Director / General Manager,  
Analyzers and Automation

[eeva-reetta.uitti@thermofisher.com](mailto:eeva-reetta.uitti@thermofisher.com)

+358 10 329 2202

[www.thermofisher.com](http://www.thermofisher.com)





# EVERY DAY, WE MAKE AN IMPACT

## OUR SOLUTION

The world leader in newborn screening systems, PerkinElmer offers screening solutions to protect the health of pregnant women and newborn babies around the world, empowering earlier disease detection, enabling more effective treatment and saving lives.

In 2020, the PerkinElmer Turku site (Wallac Oy) rapidly developed numerous COVID-19-related solutions and grew production and delivery operations significantly to aid customers internationally in combating the pandemic.

## BENEFITS & REFERENCES

In 2020, 135 million PerkinElmer tests were used to screen babies in over 90 countries for various disorders – saving the lives of around 70 babies each day.

To date, more than 12.4 million PerkinElmer® SARS-CoV-2 Real-time RT-PCR tests have been delivered from the Turku site to testing facilities internationally. The Turku site also launched a dry blood spot (DBS)-based serological test in 2020 for SARS-CoV-2 IgG using its GSP®/DELTA® platform.

## COMPANY

The Turku site is one of the largest product development and production units for PerkinElmer Inc., a USD 3.8 billion global company committed to innovating for a healthier world.

The company creates instruments, tests and software used by scientists, researchers and clinicians to address the most critical challenges across science and healthcare.

More than 90% of PerkinElmer's production from Turku is exported.

## CONTACT

**Petri Kallio**  
Managing Director, Wallac Oy

[petri.kallio@perkinelmer.com](mailto:petri.kallio@perkinelmer.com)  
+358 2 2678 111  
[www.perkinelmer.com](http://www.perkinelmer.com)

# 2.

# MEDICAL IMAGING

---

BUSINESS  
FINLAND

IMPROVED DIAGNOSTIC ACCURACY  
AND PATIENT OUTCOMES





# AI-ASSISTED CANCER DIAGNOSTICS

## OUR SOLUTION

We offer a complete portfolio of AI-based and automated tools for diagnostic support.

## BENEFITS & REFERENCES

We are currently developing a portfolio of clinical tools, called the Aiforia Clinical Suites, for the diagnosis of the most prevalent cancers in the world: prostate, breast, lung and other.

We recently had our first AI model CE-IVD marked for the diagnostic support of breast cancer and expect to CE-IVD mark one for lung cancer before the end of the year.

The Clinical Suites aim to help pathologists increase the efficiency and precision of sample review, ultimately improving patient outcomes.

## COMPANY

Aiforia equips pathologists in clinical labs with the most powerful AI-based software to accelerate sample review, improve diagnostic accuracy and enhance patient outcomes.

Aiforia's science team is experienced in a variety of areas, from pathology to cancer diagnostics, and its software developers collectively hold 100+ years of experience in AI.

## CONTACT

**Emma Vehvilainen**  
Head of Marketing

[emma.vehvilainen@aiforia.com](mailto:emma.vehvilainen@aiforia.com)

+358 40 667 5204

[www.aiforia.com](http://www.aiforia.com)



# GAME-CHANGING HANDHELD OSTEOPOROSIS DIAGNOSTICS TECHNOLOGY

## OUR SOLUTION

The Bindex® point-of-care device is a handheld probe that can be plugged into the USB port of a laptop. Bindex® is very easy to use by a nurse, medical assistant or trainee. It has FDA clearance, and over 2.5 million patients to date (Oct 2021) have been measured in the US.

## BENEFITS & REFERENCES

In the US, osteoporotic fractures cost over USD 19 billion annually.. One of the biggest challenges is the centralized diagnostics in hospitals or very specialized clinics with large DXA machines (X-ray). The need is for about 14 million bone scans annually, but at the current rate, only 2.5 million can be carried out.

When 14 million Bindex® point-of-care scans are done annually for patients in the risk group, total annual savings to the US healthcare system will be over USD 3 billion.

## COMPANY

Bone Index Finland Ltd. is a digital healthcare diagnostics company. Founded in 2011 in Kuopio, Finland, the company has developed the game-changing point-of-care technology Bindex® for osteoporosis screening and diagnostics.

With Bindex Total Bone Health™, the company is also entering the fall and fracture prevention program segment in the US. The overall aim is to prevent osteoporotic fractures, improve surgical outcomes and improve the quality of life for families in the US.

## CONTACT

**Dr. Ossi Riekkinen**  
CEO

[ossi.riekkinen@boneindex.fi](mailto:ossi.riekkinen@boneindex.fi)

+358 50 363 2797

[www.bindex.us](http://www.bindex.us)

[www.totalbonehealth.com](http://www.totalbonehealth.com)



**B I N D E X**

Osteoporosis Diagnostics



# HELPING PATIENTS WITH NEUROLOGICAL DISORDERS

## OUR SOLUTION

Combinostics' cNeuro® product family provides cloud-based AI tools to support clinical decision-making about neurological disorders by both clinicians and radiologists. Our image quantification tools help interpret brain MRI images.

In addition, our proprietary technology enables combining all relevant data, including imaging, cognitive testing and biomarkers, for improved differential diagnostics and the prediction of memory disease progression.

## BENEFITS & REFERENCES

Current clinical decision-making is subjective and relies much on the physician's medical expertise and experience. Our cNeuro® tools provide insights into the patient's combined data, enabling more systematic, uniform and confident decision-making. Our CE-marked and FDA-cleared products are in clinical use in multiple centers in Europe and the US.

## COMPANY

Our deep expertise in neuroimaging, AI technologies and software development, combined with close collaboration with clinical opinion leaders, form the basis for our work.

Founded in 2014, Combinostics is a spin-off company from VTT Technical Research Centre of Finland. Our focus is on the management of neurodegenerative diseases, such as Alzheimer's.

## CONTACT


**Jyrki Lötjönen**  
CSO

[jyrki.lotjonen@combinostics.com](mailto:jyrki.lotjonen@combinostics.com)

+358 50 346 3250

[www.combinostics.com](http://www.combinostics.com)





# DIAGNOSIS AND TREATMENT THROUGH TRUE 3D VISION

## OUR SOLUTION

We believe doctors should have the best possible tools to help them treat their patients. That's why we bring advanced medical imaging software to doctors' day-to-day work. As engineers use mathematical modeling in industry, so can physicians use mathematical modeling in clinical work.

## BENEFITS & REFERENCES

With Disior software, a clinician can transform a complex 2D image series into analyzed 3D models within minutes as a part of his or her standard clinical workflow. Results are available on the spot, providing highly accurate patient-specific 3D models and clinically relevant 3D measurements.

These provide validated, objective data for diagnosis, treatment planning and outcome assessment. Our software is backed up by more than 10 peer-reviewed research articles and 3,615 datasets analyzed in 2020.

## COMPANY

The story of Disior dates back to 2016 when the founders decided to repurpose a method used in the development of mobile phones to the medical industry. As a result of years working together with medical professionals, Disior has developed tools that maximize the benefit of today's 3D medical images for better diagnostics and treatment planning.

## CONTACT

**Anna-Maria Henell**  
CEO

[anna-maria@disior.com](mailto:anna-maria@disior.com)  
+358 50 483 6433  
[www.disior.com](http://www.disior.com)

omnomics **NGS** Synthetic\_test\_CIViC\_types\_v7, Synthetic\_t

► Gene panel (All data) , phenotype, flags

► Reported variants

Search: All Text Columns Go In progress Report Do not report Not assessed Classify Flag De

Actions Edit Save

5 Consequence, Greatest Allele Freq., Classification, Read Depth, Variant Frequency Gene Name Pathogenic, U

Links	Assessment Status	Classification	Mutation Type..	Chromo	Location	Hgvsp
Gene Name: ERBB2						
Gene/Variant	Not assessed	Uncertain significance	Indel	17	37880218	p.Leu755_Thr759del
Gene Name: JAK2						
Gene/Variant	Carrier status	Uncertain significance	SNP	9	5073770	p.Val617Phe
Gene Name: MEN1						
Gene/Variant	Secondary finding	Likely pathogenic	Indel	11	64572092	p.Lys522SerfsTer42
Gene/Variant	Not assessed	Pathogenic	SNP	11	64577580	p.Met1?
Gene/Variant	In progress	Likely pathogenic	SNP	11	64575084	p.Cys246Ter
Gene Name: TP53						
Gene/Variant	Report	Uncertain significance	Indel	17	7576570	-

# ACCELERATING THE TRANSITION TO PRECISION MEDICINE

## OUR SOLUTION

Euformatics is a bioinformatics software company with years of expertise in both genetics and software development. We provide the tools to make sense of the vast amounts of data created through next-generation sequencing (NGS).

## BENEFITS & REFERENCES

Our omnomics Suite combines the world-leading quality control tool for NGS with a comprehensive and flexible variant interpretation and reporting solution, allowing medical professionals to analyze samples quickly and reliably. This ultimately generates clinical reports in just a few clicks.

Our tools are designed for a wide range of clinical applications, including the diagnoses of rare diseases, cancer and inherited genetic diseases, as well as in preconception genetic testing.

These are the most flexible tools available for NGS data, putting power in the hands of the user.

## COMPANY

We are truly a global company. Our products are used on nearly every continent, from private diagnostics labs in the US to large hospital installations in Finland and government laboratories in Australia.

We continue to be active participants in global initiatives, including the GEMMA project to study autism spectrum disorders (EU H2020), and provide our quality control tool to the largest external quality assessment providers in Europe, EMQN and GenQA.

## CONTACT

**Jamie McDonald**  
Account Executive

[jamie.mcdonald@euformatics.com](mailto:jamie.mcdonald@euformatics.com)  
+358 44 974 2734  
[www.euformatics.com](http://www.euformatics.com)



# THE MOST PRACTICAL MICROSCOPE SCANNER IN THE WORLD

## OUR SOLUTION

Grundium has developed the world's first smart portable high-precision microscope scanner for digital pathology. Our mission is to make modern diagnostics expertise available for everyone by using remote operation and a simple user interface.

## BENEFITS & REFERENCES

Grundium makes the best professional diagnosis available. This is achieved by doing something that nobody else has – applying state-of-the-art mobile technology to digital pathology.

The Ocus® portable digital microscope slide scanner makes the sharpest images in the business. Integration-ready and very easy to use, the Ocus® scanner enables both local and remote diagnosis anywhere in the world.

## COMPANY

A global leader in advanced imaging technology, Grundium was established in 2015 by ex-Nokia engineers. The Tampere-based company is democratizing digital pathology with Ocus® microscope scanners. The cutting-edge imaging solutions are based on over 20 years of experience in optics, sensors and beautiful high-precision devices.

Grundium serves various industries and businesses by enhancing quality and processes, protecting human life and safeguarding a clean environment.

## CONTACT

**Mika Kuisma**  
CEO

[mika.kuisma@grundium.com](mailto:mika.kuisma@grundium.com)  
+358 50 354 6952  
[www.grundium.com](http://www.grundium.com)





# A GLOBAL LEADER IN OPHTHALMIC DIAGNOSTICS

## OUR SOLUTION

We focus on sight-threatening pathologies. Our goal is to work on the front line of eye health and help professionals care for and save their patients' vision. Our product portfolio includes automated TrueColor imaging devices, perimeters, handheld rebound tonometers and a software platform connecting eye care. We believe that ophthalmic care should be accessible, effortless and reliable, and we aim to establish the next level of eye care.

## BENEFITS & REFERENCES

The fundus imaging systems offer unique TrueColor Confocal images rich in detail and quality for precise diagnosis. iCare perimeters combine visual field tests, fixation loss correction and non-mydriatic confocal fundus TrueColor imaging all in one exam. iCare rebound handheld tonometers enable fast and reliable intraocular pressure (IOP) measurement without anesthetic drops or air. The measurement is also safe because it does not create micro-aerosol formations.

The software platform enables secure and instant sharing of clinical imaging, referrals and other clinical correspondence between healthcare professionals.

## COMPANY

Icare Finland Oy is a part of Revenio Group Corporation, a public medtech company listed on the Helsinki Stock Exchange. In 2020, the Revenio Group's net sales totaled EUR 61.1 million.

The iCare offering consists of medical devices for the early detection of glaucoma, diabetic retinopathy and macular degeneration, as well as the monitoring of these diseases during the treatment process.

Our product lines include rebound tonometers, fundus imaging systems, perimeters and a software platform connecting eye care.

## CONTACT

**Tomi Karvo**  
Sales and Marketing Director

[tomi.karvo@icare-world.com](mailto:tomi.karvo@icare-world.com)  
+358 40 544 9528  
[www.icare-world.com](http://www.icare-world.com)

# icare



# PREVENTING BLINDNESS WITH AN AI-INTEGRATED HANDHELD FUNDUS CAMERA

## OUR SOLUTION

Optomed's Aurora IQ handheld fundus camera uses artificial intelligence to automatically screen blinding eye diseases such as diabetic retinopathy in seconds, thus helping smaller clinics and primary care clinics make their eye screening programs accessible to more patients.

## BENEFITS & REFERENCES

Effective eye screening prevents diabetes-related blindness and reduces overall healthcare costs. Optomed's Aurora IQ includes an optional AI service to analyze diabetic retinopathy changes, for example.

AI algorithms support ophthalmologists and eye specialists in eye screening, image grading, diagnosing and treatment planning. It is possible to replace the first-line grader with AI, freeing eye specialist resources to focus on patients with the diagnosed disease. Today, many of Optomed's customers are performing eye screenings with AI throughout Europe, the Americas, Asia Pacific and Africa.

## COMPANY

Founded in 2004, Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld fundus cameras with software and artificial intelligence to transform the diagnostic process of eye diseases, such as rapidly increasing diabetic retinopathy.

## CONTACT

**Laura Piila**  
Vice President, Devices

[laura.piila@optomed.com](mailto:laura.piila@optomed.com)  
+358 40 588 1187  
[www.optomed.com](http://www.optomed.com)



# MEDICAL IMAGING EXCELLENCE

## OUR SOLUTION

Planmed is proud to be one of the world's leading companies in the fight against breast cancer through sophisticated technology. We offer a comprehensive product portfolio in the field of mammography.

Our product line consists of solutions suitable for anything from digital and analog breast cancer screening to diagnostic examinations, such as breast tomosynthesis and stereotactic biopsies.

## BENEFITS AND REFERENCES

Planmed products are well known for their user-friendliness and ergonomics. Outstanding image quality and high performance make the **Planmed Clarity™** product family one of the most advanced mammography systems in the market.

Today, Planmed's medical imaging solutions can be found in more than 80 countries worldwide. We are continuously expanding and providing our latest technology to clinics and hospitals around the world.

## COMPANY

Part of the Finnish Planmeca Group, Planmed Oy was established in 1987 in Helsinki, Finland.

We develop, manufacture and offer advanced medical imaging solutions for mammography and computed tomography. With in-house researchers and designers dedicated to emerging technologies, we are always one step ahead. We are also an industry-leading forerunner in 3D orthopedic as well as head and neck imaging with our advanced and unique computer tomography (CT) system, **Planmed Verity®**.

## CONTACT

**Jan Moed**  
Managing Director


[jan.moed@planmed.com](mailto:jan.moed@planmed.com)  
+358 20 779 5387  
[www.planmed.com](http://www.planmed.com)



# 3. PATIENT AND HOME MONITORING

---

SOLUTIONS FOR EMPOWERING A HEALTHIER  
LIFE FOR PATIENTS



# REDEFINING NEUROLOGICAL MONITORING SOLUTIONS

## OUR SOLUTION

SOENIA® offers CE-marked, ultra-long-term remote monitoring solutions to improve digital care pathways for neurological diseases.

Our clinically proven system delivers patient-reported symptoms in real time to their health-care providers. Additionally, we are developing a complementary subdermal SOENIA® UltimateEEG™ implant for monitoring electroencephalograms (EEG).

## BENEFITS & REFERENCES

The SOENIA® Medical Diary and Cloud standardizes symptom data, improves treatment adherence and reduces time spent interviewing patients about their episodic symptom history, such as seizures and migraines. This eliminates the need to process paper diaries. Our CE and UKCA marks are based on clinical studies performed at Tampere University Hospital, Finland. Real-time monitoring standardizes the quality of care across all patients. It potentially reduces treatment cycles and makes more timely interventions possible.

## COMPANY

BrainCare Oy is a Tampere University spin-off company. We work with patient associations, healthcare providers and pharmaceutical companies to redefine patient monitoring solutions in the neurology sector. We are committed to improving the lives of patients.

## CONTACT

**Katrina Wendel-Mitoraj**, PhD  
CEO

[katrina@soenia.com](mailto:katrina@soenia.com)

+358 44 572 6658

[www.soenia.com](http://www.soenia.com)



# INTRODUCING THE PULSE OF THE BRAIN

## OUR SOLUTION

Patented Cerenion® C-Trend® technology reveals the status of the brain as one simple index – at the bedside and without requiring any changes to patient care.

The solution combines standard EEG measurement with clinically proven artificial intelligence to allow medical professionals to see how their patient's brain is doing.

## BENEFITS & REFERENCES

The technology has the potential of both improving the quality and reducing the cost of intensive care. The index works with both short-term EEG and continuous EEG, offering experts a powerful overview of the long-term measurements.

## COMPANY

Cerenion is a science-based spin-off from the University of Oulu, Finland, that develops technology for the measurement of brain function during intensive care.


Our product is manufactured in conformance with IEC 62304 and is CE marked as a Class IIb medical device in the European Union. We are ISO 13485:2016 certified.

## CONTACT

**Dr. Jukka Kortelainen, MD**  
CEO

[jukka.kortelainen@cerenion.com](mailto:jukka.kortelainen@cerenion.com)  
+358 50 447 4909  
[www.cerenion.com](http://www.cerenion.com)





# QUICKLY DETECTING HEART ARRHYTHMIAS

## OUR SOLUTION

Heart2Save's product AWARIO is a clinically approved solution that detects cardiac arrhythmias. The solution consists of a beautifully designed electrocardiogram (ECG) device and AI for arrhythmia detection.

The solution can be used where and when it matters – in people's daily lives. For healthcare professionals, AWARIO provides a reliable remote arrhythmia monitoring system to replace the 12-lead ECG.

## BENEFITS & REFERENCES

In Europe, 1.5 million people suffer from a stroke annually, and more than 430,000 people die as a result. The total cost of strokes is EUR 60 billion. The number of new strokes is increasing due to the aging population.

Our AWARIO solution enables early detection of atrial fibrillation, thus helping to prevent strokes. This brings remarkable cost savings to society and reduces human suffering.

## COMPANY

Heart2Save is a health tech company founded in Kuopio in 2015. You could say our story began in a helicopter. After everything Emergency Doctor Helena Jäntti saw and experienced in her work, she got the idea of a device that could quickly and reliably detect heart arrhythmias before they cause serious consequences. Heart2Save Oy was established to solve this problem.

## CONTACT

**Helena Jäntti**  
CEO

[helena.jantti@heart2save.com](mailto:helena.jantti@heart2save.com)  
+358 40 553 8438  
[www.heart2save.com](http://www.heart2save.com)



**Heart2Save**



# THE NEW FRONT LINE OF SLEEP APNEA DIAGNOSTICS

## OUR SOLUTION

Nukute offers something wonderful to over one billion people around the world. We believe our wireless human airway auscultation technology to be a worldwide game-changer in the diagnosing and treatment of ailments such as sleep apnea, asthma, COPD and ARDS.

## BENEFITS & REFERENCES

In its first phase, Nukute's innovation delivers a proven and medically CE-marked solution for home sleep apnea testing (HSAT). The solution utilizes tracheal auscultation, oxygen saturation (SpO2) measurement and the detection of sleep position.

The Nukute system focuses on providing the clinician with an efficient and reliable diagnosis through an innovative approach, adding knowledge and value to the current methods of HSAT – with ease of use and comfort for the patient.

## COMPANY

At Nukute, we strive to provide innovative solutions for an effective diagnosis of sleep apnea and many other respiratory disorders. We collaborate with leading sleep and respiratory disorder experts, clinics, university hospitals and industry partners globally to produce technologically advanced medical devices. Our quality system is ISO 13485 certified.

## CONTACT

**Janne Regelin**  
CMO

[janne.regelin@nukute.com](mailto:janne.regelin@nukute.com)  
+358 50 376 8277  
[www.nukute.com](http://www.nukute.com)





## DISCOVER YOUR HEART

### OUR SOLUTION

VitalSignum's Beat2Phone ECG consists of a reliable and easy-to-use wearable electrocardiogram (ECG) sensor placed on the chest and connected to a phone app with a cloud analytics service for fast, cost-effective screening of heart problems.

Beat2Phone can be worn comfortably by the patient for as long as symptoms reappear. The system has been designed to be maximally automatic to save health professionals' valuable time and effort.

### BENEFITS & REFERENCES

Beat2Phone ECG is an ideal device for primary care clinicians, cardiologists, neurologists and elderly home care professionals.

Beat2Phone ECG enables better preventive monitoring and observation of cardiac symptoms, leading to cost and time savings for healthcare professionals and a healthier life for patients.

### COMPANY

Based in Helsinki, Finland, VitalSignum Oy was founded in 2015 by a team of top medical and health tech experts from Finland.

VitalSignum Oy develops and provides simple, reliable and easy-to-use mobile health monitoring solutions and services. The company focuses on offering ECG remote monitoring solutions for detecting heart arrhythmias.

### CONTACT

**Veli-Heikki Saari**  
CEO

[veli-heikki.saari@vitalsignum.com](mailto:veli-heikki.saari@vitalsignum.com)  
+358 400 406 273  
[www.vitalsignum.com](http://www.vitalsignum.com)





# 4. CONTRACT MANUFACTURING

---

YOUR PARTNER IN DESIGNING AND  
MANUFACTURING MEDICAL DEVICES

BUSINESS  
FINLAND

# ESiOR

Creating Insights



## Data

Gain insight into your competitive advantage



## Analysis

Demonstrate your competitive advantage



## Knowledge

Transform insights into action and competitive advantage



## Communication

Make a difference with effective communication

[www.esior.fi](http://www.esior.fi)

# FROM DATA TO COMPETITIVE ADVANTAGE™

## OUR SOLUTION

ESiOR offers expert solutions for value demonstration of healthcare products, services and processes, as well as the expertise to improve efficiency and cost-effectiveness in healthcare.

In addition to research and consultancy, we provide various tools to support management and decision-making.

## BENEFITS & REFERENCES

ESiOR has a strong track record of client success, with well over 500 projects. Our scientific papers include 120+ publications, 140+ congress papers and 90+ other publications and we have multiple PhD staff members.

We have been honored with awards, had chairing and podium presentations, and are a TEHDAS permanent advisor.

Examples of our method and assessment are the PICOSTEPS framework, Current Care Guidelines, StopDia interface model, Virtual Hospital eHealth services, Isaacus data lake project, and clinical study participant recall service.

## COMPANY

ESiOR creates insights and value through expert services, research, and tools. Founded in 2006, ESiOR focuses on value creation through the data-analysis-knowledge-communication chain. We provide services, such as health economics and outcomes research, registry studies, surveys, market access, data science applications, narrative reporting, interactive modeling, and web-based tools.

We are driven by data, aim at credible insight, and no stone is left unturned when we work to find the best solutions for our clients.

## CONTACT

**Erkki Soini**  
CEO, Health Economist

[erkki.soini@esior.fi](mailto:erkki.soini@esior.fi)  
+358 400 533 971  
[www.esior.fi/en/sheor/](http://www.esior.fi/en/sheor/)



# BRINGING HEALTH TECH IDEAS TO LIFE

## OUR SOLUTION

We tailor design and development and offer flexible contract manufacturing services for medical and IVD devices to match your market and product needs.

## BENEFITS & REFERENCES

Since 1994, Innokas Medical has specialized in design, development and contract manufacturing services. Innokas serves both Nordic and global medtech players to bring their high-quality medical and IVD devices to international markets.

We tailor our services to meet our customers' specific needs – which can be anything from full-scale services, where the product meets development, manufacturing and delivery, to selected parts in between.

## COMPANY

Innokas Medical is one of the industry leaders in the Nordics, specializing in medical technology and healthcare digitalization.

We have been part of the medical technology business for over 27 years. Since 1994, we have improved the quality of peoples' lives by making health tech ideas a reality.

## CONTACT

**Antti Virtanen**  
Head of Sales

[antti.virtanen@innokasmedical.fi](mailto:antti.virtanen@innokasmedical.fi)  
+358 40 869 0722  
[www.innokasmedical.fi](http://www.innokasmedical.fi)





# DRIVING THE EVOLUTION OF MICROPLATE READERS

## OUR SOLUTION

Labrox is a growing biotech company with a strong background in developing globally successful product families.

Labrox Ltd develops and manufactures state-of-the-art instruments for different research and diagnostic applications. Our main products are plate readers and point-of-care testing devices. Our business model is mainly contract development and OEM. Labrox products are currently shipped and sold in over 150 countries through our partners. Labrox products are CE, TÜV, EN, EMC, RoHS, ISO 9001 and 13485 certified.

## BENEFITS & REFERENCES

Labrox instruments are completely modular. They are lighter and more versatile compared to major brands in the market. The instruments are easily customizable – Labrox technology can be carried under your brand.

Our low-maintenance instruments are easy to keep up to date and do not require complicated user training.

## COMPANY

Labrox was founded in 2011 in Turku, Finland, by six engineering colleagues. The fundamental idea behind Labrox is to provide turnkey solutions to the research and medical field.

Our long history in detection system development guarantees that our partners get solutions that meet the highest standards.

## CONTACT

**Ida Erling**  
Head of Diagnostics Devices

[ida.erling@labrox.fi](mailto:ida.erling@labrox.fi)  
+358 50 372 3080  
[www.labrox.fi](http://www.labrox.fi)



# VITAL INFORMATION SOLUTIONS AS A FULL SERVICE

## OUR SOLUTION

Our healthcare laboratory information system My+® is at the core of our total service. Our customers are leading experts in healthcare laboratories and diagnostics. We at Mylab ensure that the developed information systems serve our customers and meet the needs of every diagnostics unit.

Our total service model provides a carefree and reliable long-term cooperation solution for healthcare laboratories and diagnostics centers.

## BENEFITS & REFERENCES

Our My+® total service solution provides extensive support for the total testing process in laboratories, from pre-analytics to post-analytics and delivering results to patients. The core system is highly configurable and certified to meet industry requirements. It can be scaled from narrow-scope dedicated laboratory operations to wide-scale university-level multidisciplinary laboratories and from manual processes to a high extent of automation with well-designed control mechanisms. Mylab has over 30 years of experience in demanding healthcare information systems integration and recognized expertise in project management and system implementation in healthcare diagnostics.

## COMPANY

Mylab is a leading expert in healthcare laboratory and diagnostics information systems in the Nordic countries. By implementing better and more reliable technological solutions for healthcare, we facilitate longer, healthier lifespans and improved quality of life. We build success for our customers by offering them comprehensive application and integration services, as well as reliable operational services and availability – providing all-inclusive, full customer service with our products.

We bring tests results to physicians and nursing staff to help them make the right treatment decisions and provide patients with peace of mind. Human life is our core value.

By delivering data, we deliver life.

## CONTACT

**Hannu Honkala**  
VP, Head of Sales and Admin

[hannu.honkala@mylab.fi](mailto:hannu.honkala@mylab.fi)  
+358 10 678 6020  
[www.mylab.fi/en](http://www.mylab.fi/en)





# YOUR PARTNER IN MANUFACTURING SOLUTIONS

## OUR SOLUTION

Screentec is a printing house that offers manufacturing services for customers worldwide. Product lines include traditional and printed electronics for medical, diagnostic and industrial applications.

Our experts and automated, high-volume production methods support our clients in the development and manufacturing of integrated product solutions that meet quality and production cost demands.

## BENEFITS & REFERENCES

Companies choose Screentec for our full product service packages that include printed electronics, microfluidics, surface functionalization and packaging. We assist our clients from initial prototype creation to full-scale production.

Our clients do not need to change manufacturers, worry about supply changes or navigate conflicting schedules and production timelines.

Our manufacturing services are ISO 13485 and ISO 9001 certified, and our facilities include ISO 6 and 7 cleanrooms.

## COMPANY

Screentec was founded 32 years ago in Oulu, Finland, a northern high-tech city. As of 2021, we employ 90 persons in divisions that manufacture electronic user interfaces, disposable medical and diagnostics sensors and personal protection masks.

We participate in national and international consortiums, such as the EU MedPhab (photonic medical devices) project and Business Finland's Personalized Health Finland program.

## CONTACT

**Antti Tauriainen**  
CEO

[antti.tauriainen@screentec.com](mailto:antti.tauriainen@screentec.com)

+358 44 556 5822

[www.screentec.com](http://www.screentec.com)





# WORLD-CLASS ELECTRONIC MANUFACTURING SERVICES (EMS) OF MEDICAL DEVICES

## OUR SOLUTION

Suitable manufacturing solutions are available from Tepcomp regardless of whether state-of-the-art technology or a time-proven older solution is used. We can also be of assistance in various design challenges, such as when choosing components or deciding on logistics solutions.

With support from Tepcomp's product development, you will optimize your product to be suitable for serial production.

## BENEFITS & REFERENCES

Tepcomp has been manufacturing healthcare and wellness technology equipment for over 30 years and is a full-service contract manufacturer for PCBs, electrotechnical solutions and complete medical devices. Tepcomp is known for cost-effective equipment manufacture and uncompromising compliance with requirements.

Our experience in cooperating with global players and our comprehensive quality management system make us an excellent partner in the manufacture of medical devices of all sizes. Our approvals include: ISO 9001, ISO 14001, ISO 13485 and UL/ENEC.

## COMPANY

Tepcomp has more than 30 years of experience in demanding projects. Our customers include numerous Finnish and international companies from a wide range of industrial sectors. Multiple long-term customer relationships are proof of our reputation as a functional, reliable and high-quality contract manufacturer of electronics. Every year, we supply more than 5,000 shipments to over 100 customers all over the world from our factories in Turku, Finland, and Kuressaare, Estonia.

## CONTACT

Kaapo Liede

[kaapo.liede@tepcomp.fi](mailto:kaapo.liede@tepcomp.fi)

+358 40 849 0744

[www.tepcomp.fi/en/](http://www.tepcomp.fi/en/)



# CONTACT INFORMATION

**BUSINESS  
FINLAND**

## Business Finland

**Kari Klossner**, Head of Smart Life Finland Program

+358 400 717 298  
kari.klossner@businessfinland.fi

**Terhi Rasmussen**, Global Opportunity Leader, Health & Wellbeing

+45 2054 9894  
terhi.rasmussen@businessfinland.fi

**BUSINESSFINLAND.COM**



Notice: The information contained in this publication is collected from various sources and provided for your information only. Business Finland does not assume any liability for the accuracy and completeness of the information.